WASHINGTON — Sen. Bob Menendez is the poster child for a pharmaceutical industry ally.
He represents the industry stronghold of New Jersey, home to giants like Johnson & Johnson, Merck, and Bristol Myers Squibb, and he’s raked in campaign cash from pharma execs and political action committees. In negotiations over drug pricing legislation, he opposed progressives’ most aggressive plans.
The industry is likely to lose a friend if Menendez doesn’t return to Congress next year. He’s on trial for bribery charges, and pursuing a long-shot third-party bid to keep his seat. The Democrat vying to replace him, Rep. Andy Kim, has refused corporate PAC funds, and is a true believer in Democrats’ more ambitious drug pricing plans.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.
Already have an account? Log in
Already have an account? Log in
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect